{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:47:17Z","timestamp":1787878037013,"version":"build-2784847793"},"reference-count":60,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Androgen biosynthesis is physiologically necessary for generating the principal stimulus for androgen receptor (AR) signaling and thus plays an essential role for development of the normal prostate, prostate cancer growth, and the development of resistance to hormonal therapies. Testosterone and dihydrotestosterone are both potent endogenous androgens that stimulate AR signaling. While the role of gonadal androgens in stimulating prostate cancer progression has been recognized for over 80 years, the appreciation for nongonadal precursor steroids in prostate cancer has been more limited in duration of time, attention, and focus in the field. Nevertheless, the very clearly established role of nongonadal androgens in enabling prostate cancer progression, especially in the absence of gonadal testosterone, frames the essentiality of androgen metabolic processes for dictating prostate cancer clinical behavior. Here, the role of androgen metabolism in prostate cancer is reviewed, particularly within the context of hormonal therapy and hormone therapy resistance, and with emphasis on recent advances.<\/jats:p>","DOI":"10.1210\/endocr\/bqag021","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:56:08Z","timestamp":1771505768000},"source":"Crossref","is-referenced-by-count":3,"title":["Androgen metabolism in prostate cancer: recent advances"],"prefix":"10.1210","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1281-3474","authenticated-orcid":false,"given":"Nima","family":"Sharifi","sequence":"first","affiliation":[{"name":"Desai Sethi Urology Institute, University of Miami Miller School of Medicine , Miami, FL 33136 ,","place":["USA"]},{"name":"Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine , Miami, FL 33136 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2026041703262725100_bqag021-B1","first-page":"293","article-title":"Studies on prostate cancer, I: the effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"issue":"3","key":"2026041703262725100_bqag021-B2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr Rev"},{"issue":"16","key":"2026041703262725100_bqag021-B3","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"issue":"26","key":"2026041703262725100_bqag021-B4","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1200\/JCO.23.00433","article-title":"Targeting the androgen signaling axis in prostate cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026041703262725100_bqag021-B5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev-med-051418-060357","article-title":"Sex hormones and prostate cancer","volume":"71","author":"Auchus","year":"2020","journal-title":"Annu Rev Med"},{"issue":"6","key":"2026041703262725100_bqag021-B6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"2026041703262725100_bqag021-B7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev.bi.63.070194.000325","article-title":"Steroid 5 alpha-reductase: two genes\/two enzymes","volume":"63","author":"Russell","year":"1994","journal-title":"Annu Rev Biochem"},{"key":"2026041703262725100_bqag021-B8","doi-asserted-by":"crossref","first-page":"105506","DOI":"10.1016\/j.jsbmb.2019.105506","article-title":"The role of adrenal derived androgens in castration resistant prostate cancer","volume":"197","author":"Barnard","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"2026041703262725100_bqag021-B9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 advanced prostate cancer consensus conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"issue":"1","key":"2026041703262725100_bqag021-B10","first-page":"EVIDoa2300171","article-title":"Targeted inhibition of CYP11A1 in castration-resistant prostate cancer","volume":"3","author":"Fizazi","year":"2024","journal-title":"NEJM Evid"},{"issue":"2","key":"2026041703262725100_bqag021-B11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"issue":"21","key":"2026041703262725100_bqag021-B12","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"2026041703262725100_bqag021-B13","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2026041703262725100_bqag021-B14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2026041703262725100_bqag021-B15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"2026041703262725100_bqag021-B16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"10336","key":"2026041703262725100_bqag021-B17","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"2026041703262725100_bqag021-B18","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2026041703262725100_bqag021-B19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"32","key":"2026041703262725100_bqag021-B20","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026041703262725100_bqag021-B21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2026041703262725100_bqag021-B22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr Rev"},{"issue":"11","key":"2026041703262725100_bqag021-B23","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1210\/en.2013-1466","article-title":"Mechanisms of androgen receptor activation in castration-resistant prostate cancer","volume":"154","author":"Sharifi","year":"2013","journal-title":"Endocrinology"},{"key":"2026041703262725100_bqag021-B24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jsbmb.2014.11.026","article-title":"The diverse chemistry of cytochrome P450 17A1 (P450c17, CYP17A1)","volume":"151","author":"Yoshimoto","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"2026041703262725100_bqag021-B25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41585-024-00953-0","article-title":"HSD3B1, prostate cancer mortality and modifiable outcomes","volume":"22","author":"Freitas","year":"2024","journal-title":"Nat Rev Urol"},{"issue":"8","key":"2026041703262725100_bqag021-B26","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1210\/en.2010-0138","article-title":"3\u03b2-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer","volume":"151","author":"Evaul","year":"2010","journal-title":"Endocrinology"},{"issue":"5","key":"2026041703262725100_bqag021-B27","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1210\/endo-126-5-2493","article-title":"Human 3 beta-hydroxysteroid dehydrogenase\/delta 5\u2014-4isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation\/isomerization of C21 and C19 steroids","volume":"126","author":"Lorence","year":"1990","journal-title":"Endocrinology"},{"issue":"33","key":"2026041703262725100_bqag021-B28","doi-asserted-by":"crossref","first-page":"13728","DOI":"10.1073\/pnas.1107898108","article-title":"Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer","volume":"108","author":"Chang","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026041703262725100_bqag021-B29","doi-asserted-by":"crossref","first-page":"bqac218","DOI":"10.1210\/endocr\/bqac218","article-title":"Adrenal steroids and resistance to hormonal blockade of prostate and breast cancer","volume":"164","author":"Michael","year":"2023","journal-title":"Endocrinology"},{"issue":"20","key":"2026041703262725100_bqag021-B30","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1158\/1078-0432.CCR-17-1313","article-title":"Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues","volume":"23","author":"Dai","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026041703262725100_bqag021-B31","doi-asserted-by":"publisher","first-page":"S1471-4914(25)00170-4","DOI":"10.1016\/j.molmed.2025.07.004","article-title":"Prostate cancer germline variants with therapeutic implications","author":"Bitaraf","year":"2025","journal-title":"Trends Mol Med"},{"key":"2026041703262725100_bqag021-B32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","article-title":"AKR1C3 (type 5 17beta-hydroxysteroid dehydrogenase\/prostaglandin F synthase): roles in malignancy and endocrine disorders","volume":"489","author":"Penning","year":"2019","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"2026041703262725100_bqag021-B33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1749-6632.2009.03700.x","article-title":"Steroid hormone transforming aldo-keto reductases and cancer","volume":"1155","author":"Penning","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"2026041703262725100_bqag021-B34","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"2026041703262725100_bqag021-B35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.mce.2017.08.016","article-title":"Intracrine androgen biosynthesis, metabolism and action revisited","volume":"465","author":"Schiffer","year":"2018","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2026041703262725100_bqag021-B36","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1152\/physrev.00020.2012","article-title":"11beta-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action","volume":"93","author":"Chapman","year":"2013","journal-title":"Physiol Rev"},{"issue":"1-2","key":"2026041703262725100_bqag021-B37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.mce.2013.07.006","article-title":"11beta-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?","volume":"377","author":"Storbeck","year":"2013","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"2026041703262725100_bqag021-B38","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2013.07.029","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","volume":"154","author":"Chang","year":"2013","journal-title":"Cell"},{"issue":"9","key":"2026041703262725100_bqag021-B39","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1210\/en.2019-00366","article-title":"HSD3B1 genotypes conferring adrenal-restrictive and adrenal-permissive phenotypes in prostate cancer and beyond","volume":"160","author":"Sabharwal","year":"2019","journal-title":"Endocrinology"},{"key":"2026041703262725100_bqag021-B40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.urology.2020.08.028","article-title":"Germline HSD3B1 genetics and prostate cancer outcomes","volume":"145","author":"Thomas","year":"2020","journal-title":"Urology"},{"issue":"3","key":"2026041703262725100_bqag021-B41","doi-asserted-by":"crossref","first-page":"e243402","DOI":"10.1001\/jamanetworkopen.2024.3402","article-title":"Adrenal-permissive HSD3B1 genotype-an invisible stimulator of prostate cancer mortality","volume":"7","author":"Schiffer","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2026041703262725100_bqag021-B42","doi-asserted-by":"crossref","first-page":"e242976","DOI":"10.1001\/jamanetworkopen.2024.2976","article-title":"Association between adrenal-permissive germline HSD3B1 allele and prostate cancer outcomes in the veterans affairs health system","volume":"7","author":"McKay","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"26","key":"2026041703262725100_bqag021-B43","doi-asserted-by":"crossref","first-page":"e2422267122","DOI":"10.1073\/pnas.2422267122","article-title":"Fine structural design of 3betaHSD1 inhibitors for prostate cancer therapy","volume":"122","author":"He","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026041703262725100_bqag021-B44","doi-asserted-by":"crossref","first-page":"e163498","DOI":"10.1172\/JCI163498","article-title":"BMX controls 3betaHSD1 and sex steroid biosynthesis in cancer","volume":"133","author":"Li","year":"2023","journal-title":"J Clin Invest"},{"issue":"12","key":"2026041703262725100_bqag021-B45","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1172\/JCI105499","article-title":"17-hydroxylation deficiency in man","volume":"45","author":"Biglieri","year":"1966","journal-title":"J Clin Invest"},{"key":"2026041703262725100_bqag021-B46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jsbmb.2016.02.002","article-title":"Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic","volume":"165","author":"Auchus","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"2026041703262725100_bqag021-B47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"33","key":"2026041703262725100_bqag021-B48","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026041703262725100_bqag021-B49","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834016642370","article-title":"CYP17 inhibitors in prostate cancer: latest evidence and clinical potential","volume":"8","author":"Alex","year":"2016","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"2026041703262725100_bqag021-B50","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-22-0115","article-title":"First-in-class small molecule to inhibit CYP11A1 and steroid hormone biosynthesis","volume":"21","author":"Karimaa","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"4_suppl","key":"2026041703262725100_bqag021-B51","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1200\/JCO.2024.42.4_suppl.159","article-title":"MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results","volume":"42","author":"Fizazi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026041703262725100_bqag021-B52","doi-asserted-by":"crossref","first-page":"10611","DOI":"10.1038\/s41467-025-66558-2","article-title":"A bypass gateway from cholesterol to sex steroid biosynthesis circumnavigates CYP17A1","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"2026041703262725100_bqag021-B53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cmet.2006.11.012","article-title":"Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice","volume":"5","author":"Chen","year":"2007","journal-title":"Cell Metab"},{"issue":"1","key":"2026041703262725100_bqag021-B54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cmet.2014.05.013","article-title":"The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha","volume":"20","author":"Umetani","year":"2014","journal-title":"Cell Metab"},{"issue":"6564","key":"2026041703262725100_bqag021-B55","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.abf8403","article-title":"Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis","volume":"374","author":"Pernigoni","year":"2021","journal-title":"Science"},{"issue":"5","key":"2026041703262725100_bqag021-B56","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41564-025-01979-9","article-title":"An expanded metabolic pathway for androgen production by commensal bacteria","volume":"10","author":"Wang","year":"2025","journal-title":"Nat Microbiol"},{"issue":"36","key":"2026041703262725100_bqag021-B57","doi-asserted-by":"crossref","first-page":"33920","DOI":"10.1074\/jbc.M306370200","article-title":"Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice","volume":"278","author":"Dawson","year":"2003","journal-title":"J Biol Chem"},{"issue":"Suppl","key":"2026041703262725100_bqag021-B58","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1194\/jlr.R800026-JLR200","article-title":"Fifty years of advances in bile acid synthesis and metabolism","volume":"50","author":"Russell","year":"2009","journal-title":"J Lipid Res"},{"key":"2026041703262725100_bqag021-B59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000321209","article-title":"The physiology and biochemistry of adrenarche","volume":"20","author":"Auchus","year":"2011","journal-title":"Endocr Dev"},{"key":"2026041703262725100_bqag021-B60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02834","article-title":"Trial design and objectives for patients with prostate cancer: recommendations from prostate cancer working group 4","author":"Armstrong","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqag021\/67099976\/bqag021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/4\/bqag021\/68099732\/bqag021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/4\/bqag021\/68099732\/bqag021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:26:44Z","timestamp":1776410804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqag021\/8496690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,6]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqag021","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,24]]},"article-number":"bqag021"}}